Document is current
Any future updates will be listed below
-
Authors
DeLacey, Sean https://orcid.org/0000-0002-7955-5732
Papadakis, Jaclyn https://orcid.org/0000-0002-8556-2509
James, Steven https://orcid.org/0000-0002-3928-9206
Cudizio, Laura
Ng, Sze May https://orcid.org/0000-0002-3449-0541
Lyons, Sarah K. https://orcid.org/0000-0002-3686-0112
Maruthur, Nisa M. https://orcid.org/0000-0002-5799-104X
Araszkiewicz, Aleksandra https://orcid.org/0000-0002-4955-6099
Gomber, Apoorva https://orcid.org/0000-0002-9955-9917
Snoek, Frank J. https://orcid.org/0000-0001-9563-6762
Toft, Eva https://orcid.org/0000-0003-1087-445X
de Beaufort, Carine https://orcid.org/0000-0003-4310-6799
Weissberg-Benchell, Jill https://orcid.org/0000-0002-4396-6337
- License Information
-
More Information
Article History
Accepted: 14 January 2025
First Online: 1 February 2025
Declarations
:
: Dr. Maruthur has a licensing agreement with Johns Hopkins HealthCare related to a co-invented virtual diabetes prevention program for adults with prediabetes and received travel support from the European Association for the Study of Diabetes (EASD). Dr. Snoek has received consulting fees from Abbott, has been a speaker for Abbott, is on the ethics committee for the INODIA trial, and is a member of the consensus committee for the European Association for the Study of Diabetes/American Diabetes Association for Type 1 diabetes management and transition of care. Dr. Snoek's institution has received research funding from Sanofi and Novo Nordisk. Dr. Ng has received a Diabetes UK grant for the UNBIASED study, received speaker fees from Insulet and Sanofi, and is a director of Brendarco LtD which undertakes mediolegal work.
: The authors declare no competing interests.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
